Paediatric Burkitt lymphoma patient-derived xenografts capture
disease characteristics over time and are a model for therapy

J 2021

Paediatric Burkitt lymphoma patient-derived xenografts capture disease characteristics over time and are a model for therapy

FORDE, S.; J.D. MATTHEWS; L. JAHANGIRI; L. LEE; N. PROKOPH et al.

Základní údaje

Originální název

Paediatric Burkitt lymphoma patient-derived xenografts capture disease characteristics over time and are a model for therapy

Autoři

FORDE, S.; J.D. MATTHEWS; L. JAHANGIRI; L. LEE; N. PROKOPH; T.I. MALCOLM; O. GIGER; N. BELL; H. BLAIR; A. O'MARCAIGH; O. SMITH; L. KENNER; S. BOMKEN; G.A.A. BURKE a Suzanne Dawn TURNER

Vydání

BRITISH JOURNAL OF HAEMATOLOGY, 2021, 0007-1048

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 8.615

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14740/21:00124569

Organizační jednotka

Středoevropský technologický institut

Klíčová slova anglicky

Burkitt lymphomapatient derived xenograftrelapseB-cell lymphomamurine cancer models

Štítky

rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 18. 5. 2022 15:16, Mgr. Pavla Foltynová, Ph.D.

Anotace

V originále

Burkitt lymphoma (BL) accounts for almost two-thirds of all B-cell non-Hodgkin lymphoma (B-NHL) in children and adolescents and is characterised by aMYCtranslocation and rapid cell turnover. Intensive chemotherapeutic regimens have been developed in recent decades, including the lymphomes malins B (LMB) protocol, which have resulted in a survival rate in excess of 90%. Recent clinical trials have focused on immunochemotherapy, with the addition of rituximab to chemotherapeutic backbones, showing encouraging results. Despite these advances, relapse and refractory disease occurs in up to 10% of patients and salvage options for these carry a dismal prognosis. Efforts to better understand the molecular and functional characteristics driving relapse and refractory disease may help improve this prognosis. This study has established a paediatric BL patient-derived xenograft (PDX) resource which captures and maintains tumour heterogeneity, may be used to better characterise tumours and identify cell populations responsible for therapy resistance.

Citovat

FORDE, S.; J.D. MATTHEWS; L. JAHANGIRI; L. LEE; N. PROKOPH; T.I. MALCOLM; O. GIGER; N. BELL; H. BLAIR; A. O'MARCAIGH; O. SMITH; L. KENNER; S. BOMKEN; G.A.A. BURKE a Suzanne Dawn TURNER. Paediatric Burkitt lymphoma patient-derived xenografts capture disease characteristics over time and are a model for therapy. BRITISH JOURNAL OF HAEMATOLOGY. 2021, roč. 192, č. 2, s. 354-365. ISSN 0007-1048. Dostupné z: https://doi.org/10.1111/bjh.17043.

@article{1852560,
   author = {Forde, S. and Matthews, J.D. and Jahangiri, L. and Lee, L. and Prokoph, N. and Malcolm, T.I. and Giger, O. and Bell, N. and Blair, H. and O'Marcaigh, A. and Smith, O. and Kenner, L. and Bomken, S. and Burke, G.A.A. and Turner, Suzanne Dawn},
   article_number = {2},
   doi = {https://doi.org/10.1111/bjh.17043},
   keywords = {Burkitt lymphomapatient derived xenograftrelapseB-cell lymphomamurine cancer models},
   language = {eng},
   issn = {0007-1048},
   journal = {BRITISH JOURNAL OF HAEMATOLOGY},
   title = {Paediatric Burkitt lymphoma patient-derived xenografts capture disease characteristics over time and are a model for therapy},
   url = {https://onlinelibrary.wiley.com/doi/10.1111/bjh.17043},
   volume = {192},
   year = {2021}
}

TY  - JOUR
ID  - 1852560
AU  - Forde, S. - Matthews, J.D. - Jahangiri, L. - Lee, L. - Prokoph, N. - Malcolm, T.I. - Giger, O. - Bell, N. - Blair, H. - O'Marcaigh, A. - Smith, O. - Kenner, L. - Bomken, S. - Burke, G.A.A. - Turner, Suzanne Dawn
PY  - 2021
TI  - Paediatric Burkitt lymphoma patient-derived xenografts capture disease characteristics over time and are a model for therapy
JF  - BRITISH JOURNAL OF HAEMATOLOGY
VL  - 192
IS  - 2
SP  - 354-365
EP  - 354-365
SN  - 00071048
KW  - Burkitt lymphomapatient derived xenograftrelapseB-cell lymphomamurine cancer models
UR  - https://onlinelibrary.wiley.com/doi/10.1111/bjh.17043
N2  - Burkitt lymphoma (BL) accounts for almost two-thirds of all B-cell non-Hodgkin lymphoma (B-NHL) in children and adolescents and is characterised by aMYCtranslocation and rapid cell turnover. Intensive chemotherapeutic regimens have been developed in recent decades, including the lymphomes malins B (LMB) protocol, which have resulted in a survival rate in excess of 90%. Recent clinical trials have focused on immunochemotherapy, with the addition of rituximab to chemotherapeutic backbones, showing encouraging results. Despite these advances, relapse and refractory disease occurs in up to 10% of patients and salvage options for these carry a dismal prognosis. Efforts to better understand the molecular and functional characteristics driving relapse and refractory disease may help improve this prognosis. This study has established a paediatric BL patient-derived xenograft (PDX) resource which captures and maintains tumour heterogeneity, may be used to better characterise tumours and identify cell populations responsible for therapy resistance.
ER  -

FORDE, S.; J.D. MATTHEWS; L. JAHANGIRI; L. LEE; N. PROKOPH; T.I. MALCOLM; O. GIGER; N. BELL; H. BLAIR; A. O'MARCAIGH; O. SMITH; L. KENNER; S. BOMKEN; G.A.A. BURKE a Suzanne Dawn TURNER. Paediatric Burkitt lymphoma patient-derived xenografts capture disease characteristics over time and are a model for therapy. \textit{BRITISH JOURNAL OF HAEMATOLOGY}. 2021, roč.~192, č.~2, s.~354-365. ISSN~0007-1048. Dostupné z: https://doi.org/10.1111/bjh.17043.

Přehled o publikaci